Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020 Market, Trends, Share, Size Research Report

Home
Pancreatic Cancer
Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020

Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020

Publisher Name » GlobalData

Published Date » 2011-10-26

Summary

GlobalDatas pharmaceuticals report, Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides Masitinib sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

Therapy area profile including patient population for the US and EU5
Analysis and review of Masitinib including sales data
Qualitative and quantitative assessment of market space
Analysis of the trends, drivers and restraints shaping and defining the markets
In-depth analysis of Masitinib including efficacy, safety, pricing, competition and other details which influence its sales potential
Detailed sales forecasts for 2013-2020 for Masitinib in the US and EU5

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of competition by understanding the changing competitive landscape
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of the drugs performance
Examine the historical sales performance of a drug in seven major markets
Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Pancreatic Cancer 4
2.2 Pancreatic Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 7
2.4.1 Cigarette Smoking 7
2.4.2 Age 7
2.4.3 Gender 8
2.4.4 Family History 8
2.4.5 Other Factors 8
2.5 GlobalData Market Forecasts Report Guidance 9

3 Pancreatic Cancer: Market Characterization 10
3.1 Pancreatic Cancer Market 10
3.2 Pancreatic Cancer Market Forecasts and CAGR 10
3.3 Drivers for Pancreatic Cancer Market 11
3.3.1 High Prevalence 11
3.3.2 High Incidence 11
3.3.3 Large Unmet Need 12

4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer 13

5 Masitinib 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Factors Affecting Sales of Masitinib 17
5.4.1 Growing Pancreatic Cancer Market 17
5.4.2 High Efficacy 17
5.4.3 Orphan Drug Designation 17
5.4.4 Large Unmet Need 17
5.4.5 Low Safety Profile 18
5.5 Drug Evaluation 18
5.5.1 Drug Risk Benefit Score 18
5.5.2 Intensity of Competition 19
5.6 Sales Forecasts 19
5.6.1 Target Patient Pool of Masitinib 19
5.6.2 Dosing 20
5.6.3 Market Penetration 20
5.6.4 Annual Cost of Therapy 21
5.6.5 Sales Projections of Masitinib 22

6 Pancreatic Cancer Market: Appendix 30
6.1 Market Definitions 30
6.2 List of Abberiviations 30
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 34
6.4 Contact Us 34
6.5 Disclaimer 34
6.6 Sources 34

List of Tables

Table 1: Pancreatic Cancer, Incidence and Mortality, 20082030 6
Table 2: Pancreatic Cancer, Global, Market Size Forecasts ($m), 20092020 10
Table 3: Detailed TNM Classification 14
Table 4: Drug Risk Benefit Score 18
Table 5: Masitinib, Pancreatic Cancer, Global, Sales Forecasts ($m), 20132020 22
Table 6: Masitinib, Pancreatic Cancer, The US, Sales Forecasts ($m), 20132020 23
Table 7: Masitinib, Pancreatic Cancer, The UK, Sales Forecasts ($m), 20132020 24
Table 8: Masitinib, Pancreatic Cancer, France, Sales Forecasts($m), 20132020 25
Table 9: Masitinib, Pancreatic Cancer, Germany, Sales Forecasts ($m), 20132020 26
Table 10: Masitinib, Pancreatic Cancer, Italy, Sales Forecasts ($m), 20132020 27
Table 11: Masitinib, Pancreatic Cancer, Spain, Sales Forecasts ($m), 20132020 28

List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Average Incidence Rate per 100,000, Pancreatic Cancer, The US, Both Sexes, 19922007 7
Figure 3: Incidence Rate per 100,000, Pancreatic Cancer, The US, Both Sexes, 20102030 8
Figure 4: Pancreatic Cancer, Global, Market Size Forecasts ($m), 20092020 10
Figure 5: Pancreatic Cancer, Worldwide, Incidence (in million), 20082030 11
Figure 6: Oncology, Worldwide, Incidence (in million), 20082030 12
Figure 7: Broad Classification of Pancreatic Cancer 13
Figure 8: Classification of Pancreatic Cancer in the US 15
Figure 9: Classification of Pancreatic Cancer in EU and Japan 15
Figure 10: Drug Model Diagram of Masitinib, The US 19
Figure 11: Drug Model Diagram of Masitinib, EU and Japan 20
Figure 12: Masitinib, Pancreatic Cancer, Global, Sales Forecasts ($m), 20132020 22
Figure 13: Masitinib, Pancreatic Cancer, The US, Sales Forecasts ($m), 20132020 23
Figure 14: Masitinib, Pancreatic Cancer, The UK, Sales Forecasts ($m), 20132020 24
Figure 15: Masitinib, Pancreatic Cancer, France, Sales Forecasts($m), 20132020 25
Figure 16: Masitinib, Pancreatic Cancer, Germany, Sales Forecasts ($m), 20132020 26
Figure 17: Masitinib, Pancreatic Cancer, Italy, Sales Forecasts ($m), 20132020 27
Figure 18: Masitinib, Pancreatic Cancer, Spain, Sales Forecasts ($m), 20132020 28
Figure 19: Masitinib, Pancreatic Cancer, Sales Distribution (%), By Country, 2020 29
Figure 20: Drug Model Diagram 32
Figure 21: Patients Approved for The Drug 33